Target Price | $48.50 |
Price | $1.82 |
Potential |
2,564.84%
register free of charge
|
Number of Estimates | 4 |
4 Analysts have issued a price target BioXcel Therapeutics, Inc. 2026 .
The average BioXcel Therapeutics, Inc. target price is $48.50.
This is
2,564.84%
register free of charge
$80.00
4,295.60%
register free of charge
$1.00
45.05%
register free of charge
|
|
A rating was issued by 4 analysts: 3 Analysts recommend BioXcel Therapeutics, Inc. to buy, 0 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the BioXcel Therapeutics, Inc. stock has an average upside potential 2026 of
2,564.84%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 2.27 | 4.85 |
64.49% | 113.62% | |
EBITDA Margin | -2,782.82% | -1,645.76% |
76.87% | 40.86% | |
Net Margin | -3,210.62% | -1,357.18% |
85.47% | 57.73% |
5 Analysts have issued a sales forecast BioXcel Therapeutics, Inc. 2025 . The average BioXcel Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an BioXcel Therapeutics, Inc. EBITDA forecast 2025. The average BioXcel Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
3 BioXcel Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average BioXcel Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -23.51 | -21.23 |
76.10% | 9.70% | |
P/E | negative | |
EV/Sales | 17.13 |
3 Analysts have issued a BioXcel Therapeutics, Inc. forecast for earnings per share. The average BioXcel Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
BioXcel Therapeutics, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
Rodman & Renshaw |
Locked
➜
Locked
|
Locked | Mar 19 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 30 2025 |
B of A Securities |
Locked
➜
Locked
|
Locked | Jan 07 2025 |
Canaccord Genuity |
Locked
➜
Locked
|
Locked | Jan 06 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Oct 21 2024 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 06 2024 |
Canaccord Genuity |
Locked
➜
Locked
|
Locked | Aug 30 2024 |
Analyst Rating | Date |
---|---|
Locked
Rodman & Renshaw:
Locked
➜
Locked
|
Mar 19 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 30 2025 |
Locked
B of A Securities:
Locked
➜
Locked
|
Jan 07 2025 |
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Jan 06 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Oct 21 2024 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 06 2024 |
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Aug 30 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.